HELIANTHUS ANNUUS SEED OIL
化粧品における HELIANTHUS ANNUUS SEED OIL のグローバル配合基準と処方特性とは?
HELIANTHUS ANNUUS SEED OIL(CAS番号: 84776-03-4)は、化粧品処方において主に溶剤・溶媒, エモリエント剤, 皮膚コンディショニング剤として配合される原料です。日本厚労省/JCIA(規制なし)、韓国MFDS(規制なし)、欧州CosIng(規制なし)など6大法域の法定基準下で管理され、通常 2–50%(適正安定域 pH 4–8)で処方されます。
7大トラック 国別・用途別 公式全成分表示名称マトリクス
各国公的告示原典のみ収録 · 機械翻訳・任意音訳ゼロ| 法域・規制トラック | 公式全成分表示名称 | ワンクリックコピー |
|---|---|---|
| ① 韓国 (MFDS 化粧品標準名称) | Unlisted in KR MFDS | |
| ② 韓国旧名称履歴 (301 リダイレクト) | — | — |
| ③ 欧州連合 (EU CosIng EC 1223/2009) | HELIANTHUS ANNUUS SEED OIL | |
| ④ 米国一般化粧品 (US PCPC / MoCRA INCI) | HELIANTHUS ANNUUS (SUNFLOWER) SEED OIL | |
| ⑤ 米国 FDA OTC モノグラフ有効成分名 | — (米国 OTC 対象外 / 一般化粧品原料) | — |
| ⑥ 中国 (NMPA IECIC 標準中国語名称) | 未収載 — 中国《既使用化粧品原料目録 (IECIC)》未収載 | — |
| ⑦ 日本化粧品表示名称 / 医薬部外品外原規名称 (JCIA / MHLW) | HELIANTHUS ANNUUS SEED OIL (標準INCI参照 · 任意カタカナ音訳排除) |
Layer 1 — 6大法域 法定配合上限および規制ステータス
| 法域 | 規制ステータス | 配合上限 | 制限条件および一次法源出典 |
|---|---|---|---|
| 韓国 (MFDS) | 規制なし | GMP | 公的化粧品原料目録収載 (GMP基準内使用) |
| 欧州 (EU) | 規制なし | GMP | 公的化粧品原料目録収載 (GMP基準内使用) |
| 米国 (FDA) | 規制なし | GMP | 公的化粧品原料目録収載 (GMP基準内使用) |
| 中国 (NMPA) | 規制なし | GMP | 公的化粧品原料目録収載 (GMP基準内使用) |
| 日本 (MHLW) | 規制なし | GMP | 公的化粧品原料目録収載 (GMP基準内使用) |
| ASEAN (ACD) | 規制なし | GMP | 公的化粧品原料目録収載 (GMP基準内使用) |
Layer 3 Formulation Concentration Box-Plot vs. Statutory Limit
Layer 3 — 剤形別通常配合濃度 (四分位数 n≥5) & 物理化学・相溶性ガイド
| 剤形グループ | Min – Q1 – Median – Q3 – Max (%) | 処方役割・作用機序 | Source ID |
|---|---|---|---|
| 剤形群 E — 無水オイル・バーム・リップケア | 2% · 9.625% · 32.5% · 35.6% · 50% | Anhydrous balm, oil & stick structural emollient | Global Starter Formulation Library Statistical Distribution (n=7, EVONIK 6 · ELEMENTIS 1) |
| 剤形群 A — 水성化粧水・美容液・アンプル | 0.5% · 5% · 5% · 5% · 10% | Aqueous serum, toner & hydrogel matrix formulation component | Global Starter Formulation Library Statistical Distribution (n=5, EVONIK 4 · ELEMENTIS 1) |
| 剤形群 C — 洗い流し用クレンザー・シャンプー | 1% · 26% · 31% · 36% · 50% | Rinse-off cleanser & surfactant system modifier | Global Starter Formulation Library Statistical Distribution (n=6, EVONIK 5 · ELEMENTIS 1) |
| 剤形群 B — 乳液・エマルジョン・クリーム | 0.5% · 5% · 5% · 10.75% · 54.7% | Emulsion cream & lotion structural / conditioning agent | Global Starter Formulation Library Statistical Distribution (n=10, EVONIK 10) |
Stratum Corneum Penetration Depth & Bio-Spicule Transdermal Delivery
Under passive topical application, molecules diffuse tortuously through intercellular lipids. Hydrophilic compounds >500 Da remain primarily on the outer stratum corneum.
pH Stability Window (0–14), Thermal Limit & HLB Colloidal Phase Behavior
Outside pH 4–8, risk of hydrolysis, viscosity loss, or ionic dissociation increases.
Thermally stable up to 50°C during standard emulsification.
Cellular & Molecular Target Mechanism Flow
Interactive Synergy Pairings (Solid) & Incompatibility Warnings (Dashed)
Click any green synergy node to jump directly to its monograph, or click a red dashed node to inspect the chemical incompatibility mechanism.
商品名は研究者がグレードを識別するための参考表記であり、各商標権は原メーカーに帰属します。
学術・毒性・処方統合モノグラフ
Tier 1 Synthesis本原料に紐づく NIH PubMed 査読付き論文アブストラクトおよび公的毒性評価報告書のみに基づいて作成された学術要約です。
関連査読付き学術論文 (NIH PubMed) (3)
Severe contact cheilitis from cera alba and other cosmetic oils, fats and waxes in lip balms [PMID: 36582047 · 2023]
Exploring the mechanism of sunflower seed oil against Alzheimer's disease through experimental and network pharmacology studies [PMID: 39973828 · 2024]
With the prevalence of Alzheimer's disease (AD) increasing exponentially, there has been a shift in the focus of drug discovery for AD from treating the symptoms to preventing the development of the disease. Several natural compounds are extensively studied as neuroprotectives in preventing disease progression. Helianthus annuus seed oil (HA) is widely used as cooking oil and is abundant in antioxidant activity. Therefore, we evaluated the effect of HA in mice model of scopolamine-induced amnesia and explored the potential underlying mechanisms. Twenty-four male mice were administered orally with either distilled water (control and scopolamine groups) or treatment groups (HA 100 and HA 200 mg/kg) for 8 consecutive days. All groups, except the control group, received an intraperitoneal injection of scopolamine at a dose of 1 mg/kg. Subsequently, novel object recognition task for cognition assessment and open field tests for locomotory activity were performed. In addition, network analysis was performed to identify the key bioactives and targets of HA against AD. Further, the binding affinity of HA bioactives to the key targets was verified by molecular docking analysis. HA (100 mg/kg and 200 mg/kg) significantly ameliorated recognition memory compared to the scopolamine group, suggesting the protective effect of HA against cognitive impairment. Network analysis indicated that the key bioactives of HA, chlorogenic acid, and oleic acid act through multiple targets and pathways, particularly the mitogen-activated protein kinase (MAPK) pathway, to ameliorate AD symptoms. Importantly, chlorogenic acid showed good binding affinity with MAPKs, TP53, and EP300. HA has therapeutic benefits in AD acting through the MAPK pathway. However, further studies need to be done to confirm the results derived and translate the potential use of HA as a dietary supplement for preventing AD.
Physical behavior of purified and crude wax obtained from sunflower (Helianthus annuus) seed oil refineries and seed hulls [PMID: 12906355 · 2003]
The sunflower seed waxes obtained from two sources (i) seed hull as a standard and (ii) crude wax from oil refineries were studied for their crystallization, melting characteristics and morphology of crystals. The results of differential scanning calorimetry of wax obtained from seed hulls showed the melting temperature range of 13.18 degrees C with the onset at 62.32 degrees C, for purified wax, compared to the melting range of 24.73 degrees C with the onset at 42.3 degrees C. for crude wax. The enthalpy of fusion for both waxes were 57.55 mcal/mg and 7.63 mcal/mg, respectively. The DSC melt crystallization temperature range was 15.79 degrees C with the onset of 64.58 degrees C for purified wax and temperature range of 31.45 degrees C with an onset of 57.76 degrees C for crude wax. A similar pattern was observed of wax obtained from the crude wax of oil refineries. The enthalpy of crystallization was -64.27 mcal/mg and -7.67 mcal/mg, respectively. The purified wax obtained from the two sources (i) and (ii) were comparable with completion temperatures of 75.5 degrees C and 75.1 degrees C, respectively. The effect of inhibitor (lecithin) on crystallization of purified wax under light microscope and surface structure by scanning electron microscope were observed. Lecithin at 0.2% inhibited the crystallization but nucleation was unaltered. The wax crystal was inhibited to around 60% of the original size with 0.2% lecithin. It is concluded that the sunflower waxes studied were not comparable in their crystal properties of crude and purified states. Lecithin inhibited the crystallization of sunflower seed wax.
よくある質問 (FAQ)
- Q1. HELIANTHUS ANNUUS SEED OIL の各国公式全成分表示名称(7トラック)はどのように異なりますか?
- 日本化粧品工業連合会(JCIA)表示名称は 'HELIANTHUS ANNUUS SEED OIL (標準INCI準拠)'、米国PCPC・欧州CosIng INCIは 'HELIANTHUS ANNUUS (SUNFLOWER) SEED OIL'、中国NMPA IECIC標準中国語名は '中国IECIC未収載(機械翻訳不可)' です。
- Q2. HELIANTHUS ANNUUS SEED OIL のグローバル6大法域における法定配合基準 (Layer 1) は?
- 6大法域規制ステータス — 日本(JP): none、韓国(KR): none、欧州(EU): none、米国(US): none、中国(CN): none、ASEAN: none。
- Q3. 処方設計における HELIANTHUS ANNUUS SEED OIL の通常配合濃度 (Layer 3) と適正 pH は?
- 主要剤形 (anhydrous_balm) において通常 2〜50%(中央値 32.5%)で配合され、適正pH範囲は 4〜8 です。
- Q4. HELIANTHUS ANNUUS SEED OIL の配合禁忌 (Incompatibilities) と推奨シナジー成分は?
- 推奨シナジーペアは GLYCERIN, CAPRYLIC/CAPRIC TRIGLYCERIDE, TOCOPHEROL、配合上の注意点は Verify phase compatibility under extreme pH or high electrolyte loads です。